Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Psychedelic Medicine

Psychedelic MedicineVol. 1, No. 3 AnnouncementFree AccessRosalind Franklin Society Proudly Announces the 2022 Award Recipient for Psychedelic MedicineJamie PetersJamie PetersDepartment of Anesthesiology University of Colorado, Anschutz Medical Campus, Aurora, CO, USASearch for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/psymed.2023.29001.rfs2022AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail The Rosalind Franklin Society (RFS), in partnership with Mary Ann Liebert, Inc., publishers, enthusiastically congratulate our distinguished recipient of the 2022 annualRFS Award in Sciencefor this journal, which recognizes the outstanding research and published work of women and underrepresented minority scientists, physicians, and engineers.Jasper A. Heinsbrock, Giuseppe Gianotti, Joel Banilla, David E. Olson, and Jamie Peters. “Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model.” (June 2023): http://doi.org//10.1089/psymed.2023.0009AbstractThe potential use of psychedelic drugs as therapeutics for neuropsychiatric disorders has been limited by their hallucinogenic properties. To overcome this limitation, we developed tabernanthalog (TBG), a novel 5-HT2A agonist with reduced hallucinogenic potential. We previously demonstrated that TBG has therapeutic efficacy in a preclinical model of opioid use disorder in rats and separately in a binge model of alcohol drinking in mice. Alcohol is commonly co-used with opioids, yet preclinical models that recapitulate this comorbidity are lacking. We thus employed a polydrug model of heroin and alcohol co-use to screen the therapeutic efficacy of TBG on behavioral metrics of addiction. Whereas pre-exposure to alcohol in the home cage did not impact single-substance self-administration or relapse rates in this model, rats were subsequently allowed to co-self-administer heroin and alcohol. This allowed us to test the effects of TBG on motivation for each substance, measured as break points in a progressive ratio test, where the amount of effort required to obtain a single reward increases exponentially with each earned reward. TBG effectively reduced motivation for heroin and alcohol in this test, indicating its efficacy is preserved in animals with a history of heroin and alcohol polydrug use.BiosketchDr. Jamie Peters is an associate professor of anesthesiology at the University of Colorado Anschutz Medical Campus. Her research focuses on the neural circuits controlling drug-seeking behaviors, including circuits that promote addiction pathology, as well as those that limit it. Her work led to the identification of a neural circuit that functions as a limiter of drug seeking in preclinical rodent models of addiction. Dr. Peters has been searching for a common limiter circuit capable of diminishing a broad spectrum of addictive behaviors. In a seminal Nature paper with Dr. David Olson's group (2021), Dr. Peters showed a striking long-lasting therapeutic effect of a single treatment with the psychedelic-like compound tabernanthalog, a synthetic derivative of ibogaine, on relapse to heroin seeking in rats. She also serves on the editorial board of Psychedelic Medicine.FiguresReferencesRelatedDetails Volume 1Issue 3Sep 2023 InformationCopyright 2023, Mary Ann Liebert, Inc., publishersTo cite this article:Jamie Peters.Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Psychedelic Medicine.Psychedelic Medicine.Sep 2023.121-121.http://doi.org/10.1089/psymed.2023.29001.rfs2022Published in Volume: 1 Issue 3: September 13, 2023Online Ahead of Print:August 14, 2023PDF download